Stefano Del Prato

Sep 16, 2024 | dom-pubs.onlinelibrary.wiley.com | Hertzel C. Gerstein |Stefano Del Prato |Renato D. Lopes |Richard E. Pratley

1 BACKGROUND/CONTEXT Glucagon-like-peptide-1 receptor agonists (GLP-1 RA) lower HbA1c by promoting insulin secretion in response to elevated glucose (the incretin effect).1, 2 They also slow gastric emptying; reduce appetite, weight, blood pressure, low-density lipoprotein (LDL) cholesterol and serious health outcomes3; and increase heart rate and pancreatic enzymes. The degree to which these nonglycaemic effects mediate their glycaemic effects remains unclear.

Apr 8, 2024 | jacc.org | James L. Januzzi |Javed Butler |Stefano Del Prato |Justin A. Ezekowitz

References1. "Heart failure: an underappreciated complication of diabetes. A consensus report of the American Diabetes Association". Diabetes Care . 2022;45:7: 1670-1690. 2. "High prevalence of previously unknown heart failure and left ventricular dysfunction in patients with type 2 diabetes". Diabetologia . 2012;55:8: 2154-2162. 3.